Ketamine's brain impact under the scanner: new study targets synaptic loss
NCT ID NCT02734602
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses PET and MRI scans to measure brain cell connections in people with major depression or PTSD. Researchers will give ketamine to see if it can reverse synaptic loss linked to these conditions. The goal is to understand brain changes, not to provide treatment. About 130 adults aged 18-70 will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ketamine
- What this could lead to
- If successful, this could reveal how ketamine affects brain connections in depression and PTSD, pointing toward new treatment targets.
- What could go wrong
- This is an early imaging study, not a treatment trial. It may not show clear changes, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PET Center
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway ease teen depression?
- Can a nasal spray break through tough depression?
- Could a new drug offer hope for Treatment-Resistant depression?
- Targeting depression: can MRI-Guided brain zaps rewire key circuits?
- Can a psychedelic trip plus a gentle ear zap lift depression?
- Can a web app get people moving in mental health residential care?